NeuroMetrix, Inc. (NURO)
| Market Cap | 60.03M |
| Revenue (ttm) | 8.21M |
| Net Income (ttm) | -1.17M |
| Shares Out | 3.80M |
| EPS (ttm) | -0.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 578,003 |
| Open | 10.60 |
| Previous Close | 11.34 |
| Day's Range | 10.16 - 10.94 |
| 52-Week Range | 1.39 - 38.75 |
| Beta | 3.07 |
| Analysts | n/a |
| Price Target | 50.00 (+377.6%) |
| Est. Earnings Date | Oct 21, 2021 |
About NURO
NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to ...
Financial Performance
In 2020, NeuroMetrix's revenue was $7.38 million, a decrease of -20.43% compared to the previous year's $9.27 million. Losses were -$2.09 million, -44.55% less than in 2019.
Financial StatementsNews
These two stocks gained 30% and 80% on Friday: here's why
The stock market is usually not very exciting on the last day of the week. But some stocks still tend to stir things up a little bit.
What's Going On With NeuroMetrix Shares Today?
NeuroMetrix Inc (NASDAQ: NURO) shares are surging higher Friday on abnormally high volume amid an increase in retail investor interest around the low-float stock. The average session volume is just unde...
NuroMetrix Pushes Higher Friday: What's Next?
NuroMetrix Inc. (NASDAQ:NURO) shares are trading higher Friday after the company began seeing increased retail interest in the stock. The stock has been seeing above average volume the past couple of da...
NURO Stock: 9 Things to Know About NeuroMetrix as Meme Stock Investors Send Shares Soaring
NeuroMetrix (NURO) is rocketing higher on Friday as retail investors short-squeeze share of the medical device company's stock. The post NURO Stock: 9 Things to Know About NeuroMetrix as Meme Stock Inve...
3 Most-Shorted Stocks to Buy After Earnings Beats
These most-shorted stocks have more than just apes to do their bidding, they offer earnings power and price charts to buy. The post 3 Most-Shorted Stocks to Buy After Earnings Beats appeared first on In...
NeuroMetrix May Struggle to Stay at Double-Digit Prices
NURO stock is an interesting opportunity for sure. But it may be best to wait for it to head back to single-digit prices before buying.
NueroMetrix Stock Looks Strong Following Its Positive Catalysts
NURO stock received attention from Reddit, but it should interest investors because of its other positive characteristics. The post NueroMetrix Stock Looks Strong Following Its Positive Catalysts appear...
Try NeuroMetrix Stock for a Stake in Breakthrough Medical Technology
It's true that NURO stock could be the target of a massive short squeeze, but NeuroMetrix's medical and financial progress is also notable. The post Try NeuroMetrix Stock for a Stake in Breakthrough Med...
NeuroMetrix Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its Wearable Neurostimulation Tec...
WOBURN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication titled “Effects of Wearable Transcutaneous Electrical Nerve Stimulation on Fibromyalgia: A...
Why NeuroMetrix Stock Is Soaring Today
NeuroMetrix Inc (NASDAQ: NURO) is surging higher Thursday morning after the company announced better-than-expected financial results. NeuroMetrix reported a second-quarter earnings loss of 13 cents per...
NeuroMetrix Reports Q2 2021 Financial Results
WOBURN, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2021. The Company is a leader in proprie...
Why NeuroMetrix Shares Are Skyrocketing Today
NeuroMetrix (NASDAQ:NURO) shares are trading higher by 153% at $25.41 on continued upward momentum after the company announced that its Quell device has received Breakthrough Designation from the FDA fo...
NeuroMetrix Stock Skyrockets On FDA Update: Technical Levels To Watch
Neurometrix Inc. (NASDAQ:NURO) shares flew higher Tuesday and Wednesday on continued momentum after the company announced its Quell device received Breakthrough Designation from the FDA for treating the...
PRFX Stock: 7 Things to Know About Pharmaceutical Company PainReform Amid Heavy Trading
We're seeing lots of activity from penny stock PainReform (PRFX) on Wednesday despite a lack of news from the pharmaceutical company. The post PRFX Stock: 7 Things to Know About Pharmaceutical Company P...
NURO Stock: Why Reddit Traders Are Targeting Red-Hot NeuroMetrix Today
NURO stock is continuing its price-doubling into today. Retail investors have caught wind of NURO short selling and flocked to buy in.
4 Penny Stocks To Watch As Hedge Against Dogecoin Price Drop Today
Dogecoin price drop: An opportunity for penny stocks? The post 4 Penny Stocks To Watch As Hedge Against Dogecoin Price Drop Today appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...
NeuroMetrix Stock Surges As Its Nerve Stimulator Scores FDA Breakthrough Designation For Fibromyalgia
NeuroMetrix Inc's (NASDAQ: NURO) Quell device has received Breakthrough Designation from the FDA to treat fibromyalgia symptoms in adults. Fibromyalgia is a common form of chronic pain accompanied by fa...
NURO Stock: The ‘Breakthrough' News Rocketing NeuroMetrix Shares Higher Today
NeuroMetrix (NURO) stock is surging higher on Tuesday after getting "Breakthrough Device Designation" from the FDA for Quell. The post NURO Stock: The ‘Breakthrough' News Rocketing NeuroMetrix Shares Hi...
NeuroMetrix, Inc. Announces Date for Second Quarter 2021 Financial Results Conference Call
WOBURN, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 second quarter financial results before the opening of the market on Jul...
NeuroMetrix Reports that Quell® Technology is to be Evaluated for Neuromyelitis Optica Spectrum Disorder (NMOSD) in a...
WOBURN, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology will be used in a double-blinded, randomized, sham-controlled trial to determine w...
NeuroMetrix's Nerve Stimulator Shows Mixed Outcomes In Fibromyalgia Trial
NeuroMetrix Inc (NASDAQ: NURO) has reported that top-line results from a randomized controlled trial of Quell for fibromyalgia will be presented at two upcoming pain medicine conferences. Quell is a tra...
NeuroMetrix Reports Q1 2021 Financial Results
WOBURN, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2021. The Company is a leader in propr...
NeuroMetrix, Inc. Announces Date for First Quarter 2021 Financial Results Conference Call
WOBURN, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 first quarter financial results before the opening of the market on Apr...
NeuroMetrix, Inc. (NURO) CEO Dr. Shai Gozani on Q4 2020 Results - Earnings Call Transcript
NeuroMetrix, Inc. (NURO) CEO Dr. Shai Gozani on Q4 2020 Results - Earnings Call Transcript
NeuroMetrix Reports Q4 and Full Year 2020 Financial Results
WOBURN, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and year ended December 31, 2020. The Company is focuse...